Search

Your search keyword '"Immuno/reuma onderzoek 5 (Vastert2)"' showing total 61 results

Search Constraints

Start Over You searched for: Author "Immuno/reuma onderzoek 5 (Vastert2)" Remove constraint Author: "Immuno/reuma onderzoek 5 (Vastert2)"
61 results on '"Immuno/reuma onderzoek 5 (Vastert2)"'

Search Results

1. Recombinant Interleukin-1 Receptor antagonist is an effective first-line treatment strategy in new-onset systemic Juvenile Idiopathic Arthritis, irrespective of HLA-DRB1 background and IL1RN variants

2. Pharmacological treatment patterns in patients with juvenile idiopathic arthritis in the Netherlands: a real-world data analysis

3. Research agenda setting with children with juvenile idiopathic arthritis: Lessons learned

4. Human regulatory T cells locally differentiate and are functionally heterogeneous within the inflamed arthritic joint

5. Costs of Hospital-Associated Care for Patients With Juvenile Idiopathic Arthritis in the Dutch Health Care System

6. Factors associated with care- and health-related quality of life of caregivers of children with juvenile idiopathic arthritis

7. Real-world data reveals the complexity of disease modifying anti-rheumatic drug treatment patterns in juvenile idiopathic arthritis: an observational study

8. Anakinra in Patients With Systemic Juvenile Idiopathic Arthritis: Long-term Safety From the Pharmachild Registry

9. Long-term efficacy and safety of canakinumab in patients with mevalonate kinase deficiency: results from the randomised Phase 3 CLUSTER trial

10. Siglec-1 expression on monocytes is associated with the interferon signature in juvenile dermatomyositis and can predict treatment response

11. ZFP36 family members regulate the pro-inflammatory features of psoriatic dermal fibroblasts

12. Definition and validation of serum biomarkers for optimal differentiation of hyperferritinaemic cytokine storm conditions in children: a retrospective cohort study

13. Evaluation of Real-World Healthcare Resource Utilization and Associated Costs in Children with Juvenile Idiopathic Arthritis: A Canadian Retrospective Cohort Study

14. Serum biomarkers confirming stable remission in inflammatory bowel disease

16. Pathogenesis and Treatment of Refractory Disease Courses in Systemic Juvenile Idiopathic Arthritis: Refractory Arthritis, Recurrent Macrophage Activation Syndrome and Chronic Lung Disease

17. Genomic Health Literacy Interventions in Pediatrics: Scoping Review

18. COMPARTMENTALIZATION, PERSISTENCE AND CONSERVED SHARED MOTIFS OF DOMINANT (REGULATORY) T CELL CLONES IN AUTOIMMUNE INFLAMMATION

19. Immunometabolic factors in adolescent chronic disease are associated with Th1 skewing of invariant Natural Killer T cells

20. Conserved human effector Treg cell transcriptomic and epigenetic signature in arthritic joint inflammation

21. Dutch patients, caregivers and healthcare professionals generate first nationwide research agenda for juvenile idiopathic arthritis

22. Tissue-Resident Memory T Cells in Chronic Inflammation-Local Cells with Systemic Effects?

23. Multi-omics integration identifies key upstream regulators of pathomechanisms in hypertrophic cardiomyopathy due to truncating MYBPC3 mutations

24. Costs of medication use among patients with juvenile idiopathic arthritis in the Dutch healthcare system

25. Consensus-based recommendations for the management of juvenile systemic sclerosis

26. Tocilizumab as an Effective Treatment Option in Children with Refractory Intermediate and Panuveitis

27. Developmental programming in human umbilical cord vein endothelial cells following fetal growth restriction

28. Recommendations from a James Lind Alliance priority setting partnership - a qualitative interview study

29. Whole Transcriptome Analysis Reveals Heterogeneity in B Cell Memory Populations in Patients With Juvenile Idiopathic Arthritis-Associated Uveitis

31. Transcriptome of airway neutrophils reveals an interferon response in life-threatening respiratory syncytial virus infection

32. European consensus-based recommendations for the diagnosis and treatment of rare paediatric vasculitides – the SHARE initiative: This is a correction to: Rheumatology, Volume 58, Issue 4, April 2019, Pages 656–671, https://doi.org/10.1093/rheumatology/key322

33. The Patient and Parent Perspective on Methotrexate in Recent Juvenile Idiopathic Arthritis Guidelines: Comment on the Article by Ringold et al

35. How autoinflammation may turn into autoimmune inflammation: Insights from monogenetic and complex IL-1 mediated auto-inflammatory diseases

36. Microbiome Analytics of the Gut Microbiota in Patients With Juvenile Idiopathic Arthritis: A Longitudinal Observational Cohort Study

37. Anakinra in children and adults with Still's disease

38. Seeking the state of the art in standardized measurement of health care resource use and costs in juvenile idiopathic arthritis: A scoping review

39. Restoring T cell tolerance, exploring the potential of histone deacetylase inhibitors for the treatment of juvenile idiopathic arthritis

40. The European network for care of children with paediatric rheumatic diseases: Care across borders

41. Molecular signature characterisation of different inflammatory phenotypes of systemic juvenile idiopathic arthritis

42. European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis-the SHARE initiative

43. Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five-Year Follow-Up Study

44. European consensus-based recommendations for the diagnosis and treatment of Kawasaki disease - the SHARE initiative

45. European consensus-based recommendations for the diagnosis and treatment of rare paediatric vasculitides - the SHARE initiative

46. Transcriptional and epigenetic profiling of nutrient-deprived cells to identify novel regulators of autophagy

47. Consensus-based recommendations for the management of juvenile localised scleroderma

48. Juvenile arthritis patients suffering from chronic inflammation have increased activity of both IDO and GTP-CH1 pathways but decreased BH4 efficacy: Implications for well-being, including fatigue, cognitive impairment, anxiety, and depression

50. Effect of Biologic Therapy on Clinical and Laboratory Features of Macrophage Activation Syndrome Associated With Systemic Juvenile Idiopathic Arthritis

Catalog

Books, media, physical & digital resources